Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: STM007
MIFTS: 51

Stomatitis

Categories: Oral diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Stomatitis

About this section

MalaCards integrated aliases for Stomatitis:

Name: Stomatitis 11 75 53 43 14 16 71

Classifications:

MalaCards categories:
Anatomical: Oral diseases
See all MalaCards categories (disease lists)
ICD10: 31


External Ids:

Disease Ontology 11 DOID:9637
MeSH 43 D013280
NCIt 49 C26887
SNOMED-CT 68 95361005
ICD10 31 K12.1
UMLS 71 C0038362
Sources

Summaries for Stomatitis

About this section

Disease Ontology: 11 A mouth disease that is characterized by inflammation of the mouth and lips.

MalaCards based summary: Stomatitis is related to hand, foot and mouth disease and pharyngitis, and has symptoms including oral mucosal blisters, enanthema and oral manifestations. An important gene associated with Stomatitis is VDI (Vesicular Stomatitis Virus Defective Interfering Particle Suppression), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Adenosine and Ethanol have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, breast and lung, and related phenotypes are cellular and immune system

Wikipedia: 75 Stomatitis is inflammation of the mouth and lips. It refers to any inflammatory process affecting the... more...
Sources

Related Diseases for Stomatitis

About this section

Diseases related to Stomatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 709)
# Related Disease Score Top Affiliating Genes
1 hand, foot and mouth disease 32.1 RIGI IL6 IFITM3
2 pharyngitis 31.8 TNF IL6 CSF2
3 viral infectious disease 31.5 TNF RIGI IL6 IFNA2 EIF2AK2
4 ebola hemorrhagic fever 31.3 TNF RIGI IL6 IFITM3 BST2
5 vaccinia 31.3 TNF IL6 EIF2AK2 CSF2
6 behcet syndrome 31.3 TNF IL6 IFNA2 CSF2
7 newcastle disease 31.1 TNF RIGI EIF2AK2
8 exanthem 31.1 TNF IL6 CSF2
9 candidiasis 31.0 TNF IL6 CSF2
10 encephalitis 31.0 TNF RSAD2 RIGI IL6
11 measles 31.0 RIGI IL6 EIF2AK2 ADAR
12 severe acute respiratory syndrome 31.0 TNF RIGI IL6
13 mouth disease 30.9 RIGI IL6 IFITM3 IFI35 ATG5 ATG12
14 viral encephalitis 30.9 TNF RIGI IL6
15 plague 30.8 TNF RIGI IL6
16 immune deficiency disease 30.8 TNF IL6 EIF2AK2 CSF2 BST2
17 lymphocytic choriomeningitis 30.8 RIGI IL6 ADAR
18 contact dermatitis 30.7 TNF IL6 CSF2
19 avian influenza 30.7 TNF RIGI IL6 IFITM3
20 diarrhea 30.7 TNF RIGI IL6 IFNA2
21 influenza 30.6 RSAD2 RIGI NUP98 IFITM3 IFITM2 EIF2AK2
22 common cold 30.6 TNF IL6 IFNA2 CSF2
23 hepatitis c virus 30.6 RIGI LDLR IFITM3 EIF2AK2 ATG5
24 mumps 30.5 TNF IL6 EIF2AK2
25 dengue disease 30.5 TNF RIGI IL6
26 acquired immunodeficiency syndrome 30.5 TNF IL6 IFNA2 CSF2
27 neutropenia 30.5 TNF IL6 IFNA2 CSF2
28 chikungunya 30.5 TNF RSAD2 RIGI IL6 IFITM3
29 hepatitis c 30.5 RIGI IFNA2 IFITM3 EIF2AK2 ATG5
30 herpangina 30.5 TNF RIGI IL6
31 gastroenteritis 30.5 TNF IL6 IFNA2 CSF2
32 yellow fever 30.5 RSAD2 RIGI IL6
33 adult syndrome 30.4 TP63 TNF IL6
34 erythema nodosum 30.4 TNF IL6 CSF2
35 pericoronitis 30.3 TNF IL6
36 hepatitis b 30.3 TNF RIGI IL6 IFNA2 EIF2AK2
37 fungal infectious disease 30.3 TNF IL6 CSF2
38 hepatitis 30.2 TNF RIGI IFNA2 IFITM3 EIF2AK2 ATG5
39 bronchiolitis 30.2 TNF IL6 CSF2
40 west nile virus 30.1 RSAD2 RIGI IFITM3 IFITM2
41 dengue virus 30.1 RSAD2 RIGI IFITM3 IFITM2
42 hantavirus hemorrhagic fever with renal syndrome 30.1 TNF RIGI IL6
43 poliomyelitis 30.1 TNF RIGI IL6
44 cellulitis 30.1 TNF IL6 CSF2
45 human cytomegalovirus infection 30.1 TNF RSAD2 IL6
46 bacterial pneumonia 30.1 TNF IL6 CSF2
47 respiratory allergy 30.0 TNF IL6 CSF2
48 rubella 30.0 TNF RIGI IL6
49 chronic fatigue syndrome 30.0 TNF IL6 EIF2AK2
50 leprosy 3 30.0 TNF IL6 CSF2

Graphical network of the top 20 diseases related to Stomatitis:



Diseases related to Stomatitis
Sources

Symptoms & Phenotypes for Stomatitis

About this section

UMLS symptoms related to Stomatitis:


oral mucosal blisters; enanthema; oral manifestations; burning mucosal; oral pain; sore roof of mouth (symptom)

MGI Mouse Phenotypes related to Stomatitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.93 ADAR ATG12 ATG5 BST2 CSF2 EIF2AK2
2 immune system MP:0005387 9.83 ADAR ATG5 BST2 CSF2 EIF2AK2 IFI35
3 hematopoietic system MP:0005397 9.4 ADAR ATG5 BST2 CSF2 EIF2AK2 IFNA2
Sources

Drugs & Therapeutics for Stomatitis

About this section

Drugs for Stomatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 311)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adenosine Approved, Investigational Phase 4 58-61-7 60961
2
Ethanol Approved Phase 4 64-17-5 702
3
Morphine Approved, Investigational Phase 4 57-27-2 5288826
4
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
5
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
6
Hexetidine Approved, Investigational Phase 4 141-94-6 3607
7
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
8
Ofloxacin Approved Phase 4 82419-36-1 4583
9
Chlorhexidine Approved, Vet_approved, Withdrawn Phase 4 55-56-1 2713 9552079
10
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
11
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
12
Promethazine Approved, Investigational Phase 4 60-87-7 4927
13
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
14
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
15
Povidone K30 Approved, Experimental, Withdrawn Phase 4 9003-39-8 6917 131751496
16
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 4112 126941
17
Simethicone Approved Phase 4 8050-81-5
18
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4 8001-79-4 96919
19
Ascorbic acid Approved, Nutraceutical Phase 4 50-81-7 54676860 54670067 5785
20
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
21
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
22
Lipoic acid Approved, Investigational, Nutraceutical Phase 4 1200-22-2 864 6112
23
Diethyl ether Experimental Phase 4 60-29-7 3283
24 Analgesics, Opioid Phase 4
25 Narcotics Phase 4
26 Epinephryl borate Phase 4
27 Castor Phase 4
28 Eusol Phase 4
29
Sodium Hypochlorite Phase 4
30 Citrate Phase 4
31 Cytochrome P-450 Enzyme Inhibitors Phase 4
32 Anti-Infective Agents Phase 4
33 Anti-Infective Agents, Local Phase 4
34 Vitamins Phase 4
35 Chlorhexidine gluconate Phase 4
36 Disinfectants Phase 4
37 Folate Phase 4
38 Vitamin B9 Phase 4
39 Vitamin B Complex Phase 4
40 Antioxidants Phase 4
41 Alpha-lipoic Acid Phase 4
42 Immunologic Factors Phase 4
43 Adjuvants, Immunologic Phase 4
44 Viscosupplements Phase 4
45 Aluminum hydroxide, magnesium hydroxide, drug combination Phase 4
46 Anti-Ulcer Agents Phase 4
47 Antacids Phase 4
48 Blood Substitutes Phase 4
49 Plasma Substitutes Phase 4
50
Selenium Approved, Investigational, Vet_approved Phase 3 7783-07-5, 7782-49-2 533

Interventional clinical trials:

(show top 50) (show all 297)
# Name Status NCT ID Phase Drugs
1 Efficacy of Two Different Oral Hygiene Regimens on the Incidence and Severity of Oral Mucositis in Patients Receiving Hematopoietic Stem Cell Transplantation - A Randomized Controlled Trial Unknown status NCT02662374 Phase 4 .02% Chlorohexidine Gluconate;3% Sodium Bicarbonate;Nystatin 10000U/ml;Supersaturated Calcium Phosphate
2 A Comparison of Oral Controlled-release Morphine With Transdermal Fentanyl in Nasopharyngeal Cancer Patients With Moderate or Severe Oral Mucositis Pain Induced by Chemoradiotherapy Unknown status NCT04292990 Phase 4 Fentanyl;Morphine
3 A Randomized Study on the Effects of Lactobacillus Brevis CD2 in the Prevention of Radio and Chemotherapy Induced Oral Mucositis in Head and Neck Cancer Patients. Unknown status NCT01707641 Phase 4
4 Effectiveness of Low Energy Laser Treatment in Oral Mucositis Induced by Chemotherapy and Radiotherapy in Head and Neck Cancer Unknown status NCT01876407 Phase 4
5 A Pilot Study Evaluating the Efficacy of Apremilast in the Treatment of Subjects With Severe Recurrent Aphthous Stomatitis (RAS) Completed NCT03690544 Phase 4 Apremilast 30mg
6 Local Administration of Morphine: An Evaluation of the Analgesic Effect at Stomatitis in Children Completed NCT00357942 Phase 4 morphine solution for injection;Placebo;morphine mouthwash
7 Clinical Evaluation of an Experimental Solution Based on Ricinus Communis Compared to Sodium Hypochlorite for Denture Cleansing Completed NCT02407834 Phase 4
8 Phase IV Study on the Feasibility of a Preventative/Therapeutic Approach With Benzydamine Oromucosal Solution in Radiation-induced Oral Mucositis (OM) in Patients With Head and Neck Cancer (HNC) Completed NCT05055726 Phase 4 Benzydamine Hydrochloride 0.15% w/v oromucosal solution
9 Evaluation of the Efficacy of a Hexetidine- and Chlorobutanol-based Mouthwash in the Symptomatic Treatment of Oral Lesions Due to Removable Prostheses: a Prospective, Randomized, Triple-blind Controlled Clinical Trial Completed NCT01115049 Phase 4 chlorobutanol, hexetidine;Chlorhexidine
10 A Randomized, Double-blind Study to Evaluate the Efficacy of MuGard Mucoadhesive Oral Wound Rinse for the Amelioration of Oral Mucositis in Subjects Receiving Chemoradiation Therapy for the Treatment of Cancers of the Head and Neck Completed NCT01283906 Phase 4
11 Clinical Study of the Effects of Compound Kushen Injection on Radiation-induced Oral Mucositis in Head and Neck Cancer Patients. Recruiting NCT04204382 Phase 4 Levofloxacin Injection;Compound Kushen Injection（CKI）
12 OZOCLO: a Randomized Clinical Trial for Prevention of Oral Mucositis Not yet recruiting NCT05211622 Phase 4 1. alpha acid lipoic - tables;2. ozonated oil - mouthwash;3. chlorhexidine 0,2% - mouthwash;4. sodium bicarbonate 5% solution - mouthwash
13 An Adaptive Design, Single-Blind, Randomized, Controlled Study Investigating Polyvinylpyrrolidone (PVP) and Sodium Hyaluronate-Containing Oral Gel (Gelclair®) in Comparison to Viscous Lidocaine, Diphenhydramine, and Aluminum-magnesium Hydroxide/Simethicone Antacid Suspension Mouthwash ("Magic Mouthwash") for the Management of Oral Mucositis Associated With High Dose Chemotherapy and Methotrexate in Allogeneic Stem Cell Transplant Recipients Terminated NCT03490396 Phase 4
14 Prospective, Open-label, Randomized, Control Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine Withdrawn NCT01288625 Phase 4 Amifostine
15 The Clinical Study for Evaluation of Efficacy and Safety of EGF on Oral Mucositis in Radiation Therapy Patients Unknown status NCT01099891 Phase 3 rhEGF;Placebo
16 A Randomized Trial to Evaluate the Efficacy of Selenium for the Prevention of Chemotherapy-induced Mucositis During Autologous Stem Cell Transplantation. Unknown status NCT04080622 Phase 3 Selenium;Placebos
17 Comparative Efficacy of Rebamipide Gargle And Benzydamine HCL Gargle in Prevention and Management of Chemo- and Radio-therapy-induced Oral Mucositis in Head and Neck Cancer Patients: (A Randomized Clinical Trial) Unknown status NCT04685395 Phase 3 Ribamipide gargle \benzdymine HCL gargel
18 Laser Therapy Prevents Mucositis Oral in Patients Undergoing to Chemotherapy for Bone Marrow Transplantation? A Randomized Clinical Trial. Unknown status NCT02020928 Phase 3
19 A Pilot Study on the Efficacy of Lactobacillus Brevis CD2 Lozenges in Preventing Oral Mucositis by High-dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT02085694 Phase 2, Phase 3 Lactobacillus brevis CD2
20 Evaluation of Low-energy Laser Therapy for Prevention and Reduction of Severity of Oral Mucositis in Children "Mucositis Laser 1" Unknown status NCT01007617 Phase 2, Phase 3
21 A Multinational, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial to Determine the Efficacy and Safety of IB-367 Rinse in Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck Malignancy Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
22 Prevention of Recurrent Aphthous Stomatitis Using Vitamins Completed NCT00527306 Phase 3
23 Effectiveness of Topical Hyaluronic Acid Versus Chlorhexidine Mouthwashes in the Treatment of Recurrent Aphthous Stomatitis: A Randomized Clinical Trial Completed NCT04265001 Phase 3 Hyaluronic acid in the form of hyaluronan sodium 25 mg/100 ml as a mouthwash
24 Efficacy of Standardized-propolis Extract (EPP-AF®) Gel Formulation as Buccal Antiseptic in Elderly People Completed NCT02818803 Phase 3 Miconazole
25 A Randomized,Controlled Clinical Trial on the Efficacy and Safety of Chining Decoction in the Treatment of Radiation Stomatitis. Completed NCT02303197 Phase 3 ChiNing decoction
26 Evaluating the Effectiveness of Topical Morphine Compared With a Routine Mouthwash in Managing Cancer Treatment-induced Mucositis in Patients With Head and Neck Cancer in Isfahan Completed NCT01837446 Phase 2, Phase 3 2% morphine solution;Magnesium aluminum hydroxide;2% viscous lidocaine;Diphenhydramine
27 LAMPO: Multicenter Randomized Double-blind Controlled Trial to Evaluate the Efficacy of Laser Therapy for Treatment of Oral Mucositis Induced by Chemotherapy in Children Completed NCT02762019 Phase 3
28 A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2 Completed NCT00001812 Phase 3 Nystatin
29 A Double-Blind, Randomized, Vehicle-Controlled Study Comparing the Safety and Efficacy of Benzydamine HCl 0.15% Oral Rinse Including a Separate Open-Label Standard of Care Arm in Subjects With Radiation-Induced Mucositis Completed NCT00051441 Phase 3 Benzydamine Hydrochloride 0.15% Oral Rinse
30 A Phase 3, Randomized, Double-blind, Placebo-controlled Trial of Recombinant Human Keratinocyte Growth Factor for Reduction of Mucositis in Patients With Hematologic Malignancies Undergoing Total Body Irradiation and High-dose Chemotherapy With Autologous PBPC Transplantation Completed NCT00041665 Phase 3 Recombinant Human Keratinocyte Growth Factor
31 Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (rHuKGF) for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer Receiving Radiotherapy With Concurrent Chemotherapy (RT/CT) Completed NCT00101582 Phase 3 Placebo;palifermin;cisplatin chemotherapy
32 Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation : a Randomized Double Blind Multicenter Prospective Phase III Trial Completed NCT02696408 Phase 3
33 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Study to Assess the Efficacy and Safety of SBG on Oral Mucositis in Head and Neck Cancer Patients Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT00790322 Phase 3 SBG
34 A Double-Blind, Randomized, Placebo-controlled Study of Two Different Schedules of Palifermin for Reduction in Severity of Oral Mucositis in Subjects With Multiple Myeloma Receiving Melphalan Followed by Autologous Blood Stem Cell Transplantation Completed NCT00434161 Phase 3 Palifermin before only;Placebo;Palifermin before and after
35 Clinical Effect of Probiotic Use Bifidobacterium Animalis Subsp. Lactis as Adjunctive Therapy in Non-surgical Treatment of Periimplant Mucositis: a Randomized Controlled Trial Completed NCT04187222 Phase 3
36 Laser Therapy Associated With Photodynamic Therapy in the Treatment of Oral Mucositis Induced by Chemotherapy in Young Patients: Randomized Blind Clinical Trial Completed NCT02555501 Phase 3
37 Randomized Cross-over Study of Curcumin for Prevention of Oral Mucositis in Children Receiving Doxorubicin Based Chemotherapy. Completed NCT00475683 Phase 3
38 A Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Palifermin (Recombinant Human Keratinocyte Growth Factor) for Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer Receiving 5-FU and Leucovorin as Adjuvant Therapy Completed NCT00393822 Phase 2, Phase 3 palifermin;placebo
39 Evaluate Safety and Tolerability and Compare Absorption/Distribution Kinetics of a Single 100 Mcg Dose of Fentanyl Sublingual Spray (Fentanyl SL Spray) in Cancer Subjects With or Without Oral Mucositis Completed NCT00956254 Phase 3 Fentanyl sublingual spray
40 A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck Completed NCT03237325 Phase 3 SGX942;Placebo
41 A Randomized, Blinded, Active-control Trial of Palifermin (rHuKGF) to Evaluate Oral Mucositis in Subjects With Hematologic Malignancies Undergoing Fractionated Total Body Irradiation (fTBI) and High Dose Chemotherapy With Autologous Peripheral Blood Progenitor Cell (PBPC) Transplantation Completed NCT00109031 Phase 3 palifermin;Cyclophosphamide;Etoposide;Placebo
42 A Phase II/III Blinded Randomized Trial to Determine the Efficacy of Low Energy Diode Laser Therapy (650 nm or 780 nm) to Prevent Oral Mucositis Following Bone Marrow Transplantation Completed NCT00024037 Phase 2, Phase 3
43 A Randomized Placebo-Controlled Trial of Manuka Honey for Oral Mucositis Due to Radiation Therapy for Cancer Completed NCT00615420 Phase 3
44 A Comparison of Acute Oral Mucositis Between Morning and Afternoon Radiotherapy in Patients Receiving Radiation Treatment for Cancer of the Head and Neck Completed NCT00004234 Phase 3
45 Management of Mucositis With GM-CSF (Sargramostim) Mouthwash Study Protocol Completed NCT00293462 Phase 3
46 Evaluation of Oral Care to Prevent Oral Mucositis in Estrogen Receptor Positive Metastatic Breast Cancer Patients Treated With Everolimus: Phase III Randomized Control Trial Completed NCT02376985 Phase 3 Everolimus
47 Khon Kaen University Ethics Committee in Human Research Completed NCT02536781 Phase 2, Phase 3 Anthocyanin;Placebo
48 Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (rHuKGF) for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer Receiving Adjuvant Radiotherapy and Chemotherapy(RT/CT) Completed NCT00131638 Phase 3 Placebo;Palifermin
49 Phase III Randomized Double-blind Cross-over Trial of Caphosol® Versus NaCl 0.9% in the Relief of Oral Mucositis in Renal Cell Carcinoma, Hepatocellular Carcinoma, and Gastrointestinal Stromal Tumor Patients Receiving Targeted Therapy Completed NCT01265810 Phase 3
50 Phase III Trial of Low-level Laser Therapy to Prevent Induced Oral Mucositis in Head and Neck Cancer Patients Submitted to Concurrent Chemoradiation Completed NCT01439724 Phase 3

Search NIH Clinical Center for Stomatitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


carbamide peroxide
Sucralfate

Cochrane evidence based reviews: stomatitis

Sources

Genetic Tests for Stomatitis

About this section
Sources

Anatomical Context for Stomatitis

About this section

Organs/tissues related to Stomatitis:

MalaCards : Bone Marrow, Breast, Lung, Myeloid, Liver, T Cells, Bone
Sources

Publications for Stomatitis

About this section

Articles related to Stomatitis:

(show top 50) (show all 15754)
# Title Authors PMID Year
1
A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. 53 62
17520255 2008
2
DPYD*2A mutation: the most common mutation associated with DPD deficiency. 53 62
17165084 2007
3
Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma. 53 62
17409804 2007
4
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. 53 62
15550581 2004
5
Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy. 53 62
15539918 2004
6
Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients. 53 62
12352929 2002
7
Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. 53 62
10473079 1999
8
Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy. 53 62
9007910 1997
9
High dose busulphan/cyclophosphamide for autologous bone marrow transplantation is associated with minimal non-hemopoietic toxicity. 53 62
7524888 1994
10
Generation of Multispecies Oral Bacteria Biofilm Models. 62
36418689 2023
11
Characterization and functional analysis of chicken dsRNA binding protein hnRNPU. 62
36044969 2023
12
Cell Membrane-Anchoring Nano-Photosensitizer for Light-Controlled Calcium-Overload and Tumor-Specific Synergistic Therapy. 62
36180398 2022
13
Cloning and codon optimization of a novel feline interferon omega gene for production by Pichia pastoris and its antiviral efficacy in polyethylene glycol-modified form. 62
35068319 2022
14
A new anterograde trans-synaptic tracer based on Sindbis virus. 62
35662226 2022
15
Does microwave disinfection affect the dimensional stability of denture base acrylic resins? A systematic review. 62
34661315 2022
16
In vitro inhibition of a multispecies oral cavity biofilm by Syzygium aromaticum essential oil. 62
34633113 2022
17
Vesicular stomatitis virus sensitizes immunologically cold tumors to checkpoint blockade by inducing pyroptosis. 62
36096276 2022
18
Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India. 62
34908235 2022
19
Development of an indirect ELISA using a novel linear epitope at the C-terminal region of the VP2 protein to specifically detect antibodies against Senecavirus A. 62
36461023 2022
20
Drug Receives New Indication for Pediatric Graft-Versus-Host Disease. 62
36384792 2022
21
RNA-seq and LC-MS/MS analysis of antiviral effects mediated by cold stress and stress hormone corticosterone in chicken DF-1 cells. 62
36308941 2022
22
Ischemic stroke is a potential complication of uncontrolled inflammation in mevalonate kinase deficiency - A case report. 62
36242899 2022
23
Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin's lymphoma: an open-label, multicenter, dose-escalation phase 1 study. 62
36107394 2022
24
Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α. 62
35973806 2022
25
Efficacy of 5-aminolevulinic acid-mediated photodynamic therapy in patients with nicotine stomatitis. 62
36469966 2022
26
Osimertinib in the Treatment of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer: A Meta-Analysis. 62
36470213 2022
27
Oral health-related quality of life in children with celiac disease. 62
35918470 2022
28
Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies. 62
36240432 2022
29
Use and efficacy of mouthwashes in elderly patients: A systematic review of randomized clinical trials. 62
36402239 2022
30
Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy. 62
36470258 2022
31
Does having MEFV gene sequence variants affect the clinical course and colchicine response in children with PFAPA syndrome? 62
36376520 2022
32
PTX Treatment of Colon Cancer: Mode of Action Based on Tumor Marker and Cytokine Kinetics. 62
36288885 2022
33
Membrane Sphingomyelin in Host Cells Is Essential for Nucleocapsid Penetration into the Cytoplasm after Hemifusion during Rubella Virus Entry. 62
36346228 2022
34
Oral manifestations associated with inflammatory bowel disease and early endoscopic findings in patients with spondyloarthritis. 62
36348398 2022
35
Efficacy of Everolimus Combined with 177Lu-Dotatate in the Treatment of Neuroendocrine Tumors. 62
36342790 2022
36
Resilient liner modified by antimicrobials for denture stomatitis treatment: A randomized controlled trial. 62
36122605 2022
37
The Significance of Zinc in Patients with Chronic Liver Disease. 62
36432541 2022
38
Oral lichen planus and related lesions. What should we accept based on the available evidence? 62
36371653 2022
39
Mutational escape prevention by combination of four neutralizing antibodies that target RBD conserved regions and stem helix. 62
36414178 2022
40
Prevalence of aphthous stomatitis in patients with inflammatory bowel disease after the treatment with monoclonal antibodies: a systematic review and meta-analysis. 62
36173720 2022
41
Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials. 62
36208978 2022
42
Transient T Cell Expansion, Activation, and Proliferation in Therapeutically Vaccinated Simian Immunodeficiency Virus-Positive Macaques Treated with N-803. 62
36377872 2022
43
Stomatitis and Bone Marrow Suppression Followed by Leukoerythroblastosis in a Patient on Long-Term Low-Dose Methotrexate Therapy. 62
35882283 2022
44
Functional characterization of bat IRF1 in IFN induction. 62
35933044 2022
45
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. 62
36244398 2022
46
Chronic Ulcerative Stomatitis (CUS) as an Interdisciplinary Diagnostic Challenge: A Literature Review. 62
36430253 2022
47
Tegument protein UL21 of alpha-herpesvirus inhibits the innate immunity by triggering CGAS degradation through TOLLIP-mediated selective autophagy. 62
36343628 2022
48
The Porcine Cyclic GMP-AMP Synthase-STING Pathway Exerts an Unusual Antiviral Function Independent of Interferon and Autophagy. 62
36377876 2022
49
Expansion of CD8+ T cell population in Lassa virus survivors with low T cell precursor frequency reveals durable immune response in most survivors. 62
36441765 2022
50
Recombinant vesicular stomatitis virus-vectored vaccine induces long lasting immunity against Nipah virus disease. 62
36445779 2022
Sources

Variations for Stomatitis

About this section
Sources

Expression for Stomatitis

About this section
Search GEO for disease gene expression data for Stomatitis.
Sources

Pathways for Stomatitis

About this section

Pathways related to Stomatitis according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.61 ADAR ATG12 ATG5 BST2 CSF2 EIF2AK2
2
Cytokine Signaling in Immune system 66
Show member pathways
 12.85 TNF RSAD2 RIGI NUP98 IL6 IFNA2
3
Toll-like receptor signaling pathway 74
Show member pathways
 12.72 ADAR EIF2AK2 IFNA2 IL6 RIGI TNF
4
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.42 TNF RSAD2 IL6 IFNA2 IFITM3 IFITM2
5
DDX58/IFIH1-mediated induction of interferon-alpha/beta 66
Show member pathways
 12.32 RIGI IFNA2 ATG5 ATG12
6
Cytosolic sensors of pathogen-associated DNA 66
Show member pathways
 12.2 ADAR ATG12 ATG5 IFNA2 IL6 RIGI
7
Hematopoietic Stem Cells and Lineage-specific Markers 65
11.86 TNF IL6 IFNA2 CSF2
8
Interferon gamma signaling 66
Show member pathways
 11.81 RSAD2 RIGI NUP98 IFNA2 IFITM3 IFITM2
9
Host-pathogen interaction of human coronaviruses - interferon induction 74
Show member pathways
 11.71 RIGI IFNA2 EIF2AK2 ADAR
10
Clock-controlled autophagy in bone metabolism 74
11.66 IL6 ATG5 ATG12
11
Burn wound healing 74
11.63 TNF IL6 IFNA2
12
Dendritic Cells Developmental Lineage Pathway 65
11.57 TNF IL6 IFNA2 CSF2
13
Photodynamic therapy-induced NF-kB survival signaling 74
Show member pathways
 11.54 TNF IL6 CSF2
14
Lung fibrosis 74
11.53 TNF IL6 CSF2
15
Non-genomic actions of 1,25 dihydroxyvitamin D3 74
11.43 TNF IL6 IFNA2
16
SARS-CoV-2 innate immunity evasion and cell-specific immune response 74
11.38 TNF RIGI NUP98 CSF2
17
Interleukin-10 signaling 66
11.37 TNF IL6 CSF2
18
Cytokines and inflammatory response 74
11.12 TNF IL6 CSF2
19
Immune infiltration in pancreatic cancer 74
11.06 TNF IL6 CSF2
20
Cells and molecules involved in local acute inflammatory response 74
Show member pathways
 10.24 TNF IL6
Sources

GO Terms for Stomatitis

About this section

Cellular components related to Stomatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Atg12-Atg5-Atg16 complex GO:0034274 8.92 ATG5 ATG12

Biological processes related to Stomatitis according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 10.25 ADAR BST2 EIF2AK2 IFI35 IFITM2 IFITM3
2 positive regulation of DNA-binding transcription factor activity GO:0051091 10.11 IL6 RIGI TNF TRIM41
3 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 10.03 TNF IL6 IFNA2 CSF2
4 negative regulation of viral genome replication GO:0045071 10.03 TNF RSAD2 IFITM3 IFITM2 EIF2AK2 BST2
5 positive regulation of chemokine production GO:0032722 10.02 TNF IL6 EIF2AK2
6 type I interferon-mediated signaling pathway GO:0060337 10.01 IFNA2 IFITM3 IFITM2
7 immune system process GO:0002376 9.97 RSAD2 RIGI IFITM3 IFITM2 IFI35 EIF2AK2
8 response to type II interferon GO:0034341 9.95 IFITM3 IFITM2 BST2
9 negative regulation of viral entry into host cell GO:0046597 9.93 IFNA2 IFITM3 IFITM2
10 autophagy of nucleus GO:0044804 9.88 ATG5 ATG12
11 vascular endothelial growth factor production GO:0010573 9.88 TNF IL6
12 regulation of autophagosome maturation GO:1901096 9.87 ATG5 ATG12
13 positive regulation of leukocyte proliferation GO:0070665 9.86 CSF2 BST2
14 response to virus GO:0009615 9.86 TNF RSAD2 RIGI IFITM3 IFITM2 EIF2AK2
15 response to interferon-beta GO:0035456 9.85 IFITM3 IFITM2 BST2
16 response to interferon-alpha GO:0035455 9.85 ADAR BST2 EIF2AK2 IFITM2 IFITM3
17 C-terminal protein lipidation GO:0006501 9.83 ATG5 ATG12
18 positive regulation of viral translation GO:1904973 9.8 ATG5 ATG12
19 defense response to virus GO:0051607 9.66 ADAR BST2 EIF2AK2 IFITM2 IFITM3 IFNA2
Sources

Sources for Stomatitis

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....